Scale Management’s Orexigen Therapeutics, Inc. OREX Stock Holding History

Scale Management’s Portfolio OREX Stock Details OREX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	$435K	Sell	131,257 -1	-0%	-$4	0.96%	4
2016 Q2	$564K	Hold	131,258	–	–	1.34%	4
2016 Q1	$735K	Hold	131,258	–	–	1.47%	5
2015 Q4	$2.26M	Hold	131,258	–	–	3.46%	5
2015 Q3	$2.77M	Sell	131,258 -24,820	-16%	-$851K	3.44%	5
2015 Q2	$7.73M	Sell	156,078 -132,353	-46%	-$7.91M	5.03%	6
2015 Q1	$22.6M	Sell	288,431 -13,314	-4%	-$826K	11.28%	4
2014 Q4	$18.3M	Buy	+301,745	New	+$15.2M	10.44%	6

Other funds holding OREX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Scale Management's OREX Position: Q3 2016 in Review

Scale Management reduced its Orexigen Therapeutics, Inc. (OREX) stake by 0% in Q3 2016, selling an estimated $4 and leaving 131,257 shares worth $435K. The position accounts for 0.96% of the portfolio, ranked #4.

Scale Management first reported a position in OREX in Q4 2014 and has held it in 8 quarters since. The position peaked at $22.6M in Q1 2015. 55 funds tracked by Wall St. Rank hold OREX as of Q3 2016.

Scale Management held 131,257 shares of Orexigen Therapeutics, Inc. worth $435K as of Q3 2016.
Scale Management sold 1 Orexigen Therapeutics, Inc. share in Q3 2016, an estimated $4.
Orexigen Therapeutics, Inc. made up 0.96% of Scale Management's portfolio in Q3 2016, its #4 holding.
Scale Management first reported a position in Orexigen Therapeutics, Inc. in Q4 2014 and has held it in 8 quarters since.
Scale Management's Orexigen Therapeutics, Inc. position peaked at $22.6M in Q1 2015.
55 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q3 2016.

Based on Scale Management's 13F filing for Q3 2016, filed 14 Nov 2016.